OncoCyte
About: OncoCyte Corp is a pioneering diagnostics technology company. Its mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers, or payers.
Employees: 49
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
25% more funds holding
Funds holding: 20 [Q3] → 25 (+5) [Q4]
2% less capital invested
Capital invested by funds: $20.4M [Q3] → $20M (-$396K) [Q4]
3.63% less ownership
Funds ownership: 53.6% [Q3] → 49.97% (-3.63%) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Needham Mike Matson 22% 1-year accuracy 27 / 121 met price target | 48%upside $4.25 | Buy Reiterated | 8 Apr 2025 |
Lake Street Thomas Flaten 40% 1-year accuracy 4 / 10 met price target | 74%upside $5 | Buy Initiated | 28 Mar 2025 |
Stephens & Co. Mason Carrico 12% 1-year accuracy 3 / 26 met price target | 39%upside $4 | Equal-Weight Reiterated | 26 Mar 2025 |
Financial journalist opinion
Based on 5 articles about OCX published over the past 30 days









